Novinky z ASCO 2018 – kolorektální karcinom
Radim Němeček |
|
HIPEC PROVIDES NO ADDITIONAL BENEFIT TO COMPLETE RESECTION IN COLORECTAL PERITONEAL CARCINOMATOSIS
Debra Gordon |
|
LONG-TERM RESULTS OF THE ADORE TRIAL: ADJUVANT OXALIPLATIN, LEUCOVORIN, AND 5-FLUOROURACIL (FOLFOX) VERSUS 5-FLUOROURACIL AND LEUCOVORIN (FL) AFTER PREOPERATIVE CHEMORADIOTHERAPY AND SURGERY FOR LOCALLY ADVANCED RECTAL CANCER
Yong Sang Hong, Sun Young Kim, Ji Sung Lee, Byung-Ho Nam, Jeong Eun Kim, Kyu-Pyo Kim, Joon Oh Park, Young Suk Park, Ji Yeon Baek, Tae-You Kim, Keun-Wook Lee, Joong Bae Ahn, Kyung Hae Jung, Tae Won Kim |
|
RANDOMIZED TRIAL OF IRINOTECAN AND CETUXIMAB (IC) VERSUS IRINOTECAN, CETUXIMAB AND RAMUCIRUMAB (ICR) AS 2ND LINE THERAPY OF ADVANCED COLORECTAL CANCER (CRC) FOLLOWING OXALIPLATIN AND BEVACIZUMB BASED THERAPY: RESULT OF E7208
Howard S. Hochster, Paul J. Catalano, Peter J. O’Dwyer, Edith P. Mitchell, Deirdre Jill Cohen, Bryan Andrew Faller, Jeremy S. Kortmansky, Sheetal Mehta Kircher, Jill Lacy, Heinz-Josef Lenz, Udit N. Verma, Al Bowen Benson, ECOG-ACRIN |
|
MFOLFOXIRI + PANITUMUMAB VERSUS FOLFOXIRI AS FIRST-LINE TREATMENT IN PATIENTS WITH RAS WILD- -TYPE METASTATIC COLORECTAL CANCER M(CRC): A RANDOMIZED PHASE II VOLFI TRIAL OF THE AIO (AIO-KRK0109)
Michael Geissler, Jorge Riera-Knorrenschild, Andrea Tannapfel, Jobst Greeve, Axel Florschütz, Swen Wessendorf, Thomas Seufferlein, Stephan Kanzler, Swantje Held, Volker Heinemann, Anke C. Reinacher-Schick, Uwe Marc Martens |
|
KEYNOTE-164: PEMBROLIZUMAB FOR PATIENTS WITH ADVANCED MICROSATELLITE INSTABILITY HIGH (MSI-H) COLORECTAL CANCER
Dung T. Le, Petr Kavan, Tae Won Kim, Matthew E. Burge, Eric Van Cutsem, Hiroki Hara, Patrick McKay Boland, Jean-Luc Van Laethem, Ravit Geva, Hiroya Taniguchi, Todd S. Crocenzi, Manish Sharma, Chloe Evelyn Atreya, Luis A. Diaz, Li Wen Liang, Patricia Marinello, Tong Dai, Bert H. O’Neil |
|
GENITOURINÁRNÍ SEKCE NA ASCO 2018
Jindřich Fínek |
|
ADJUVANT DOCETAXEL FAILS TO IMPROVE DFS FOR INTERMEDIATE- OR HIGH-RISK PROSTATE CANCER
Leah Lawrence |
|
A RANDOMIZED PHASE III TRIAL BETWEEN ADJUVANT DOCETAXEL AND SURVEILLANCE AFTER RADICAL RADIOTHERAPY FOR INTERMEDIATE AND HIGH RISK PROSTATE CANCER: RESULTS OF SPCG-13 TRIAL
Pirkko-Liisa Irmeli Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Lennart Astrom, Timo Marttila, Camilla Thellenberg-Karlsson, Sten Nilsson, Widmark Anders, Teppo Huttunen, Claes Ginman |
|
ADDING OLAPARIB TO ABIRATERONE PROLONGS RPFS IN MCRPC
Michelle Dalton |
|
OLAPARIB COMBINED WITH ABIRATERONE IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): A RANDOMIZED PHASE II TRIAL
Noel Clarke, Pawel J. Wiechno, Boris Alekseev, Nuria Sala, Robert Jones, Ivo Kocak, Vincenzo Emanuele Chiuri, Jacek Jassem, Aude Flechon, Charles Redfern, Carsten Dietrich Goessl, Joseph Burgents, Robert Kozarski, Darren R. Hodgson, Fred Saad |
|
VAKCÍNA NA BÁZI DENDRITICKÝCH BUNĚK (DENDRITIC CELL VACCINE, DCVAC) PODÁVANÁ S CHEMOTERAPIÍ PACIENTKÁM S EPITELIÁLNÍM OVARIÁLNÍM KARCINOMEM (EPITHELIAL OVARIAN CARCINOMA, EOC) PO PRIMÁRNÍ CHIRURGICKÉ LÉČBĚ (PRIMARY DEBULKING SURGERY, PDS): PRŮBĚŽNÁ ANALÝZA OTEVŘENÉHO RANDOMIZOVANÉHO MULTI-CENTRICKÉHO KLINICKÉHO HODNOCENÍ FÁZE 2
Lukáš Rob, Peter Mallmann, Pawel Knapp, Bohuslav Melichar, Jaroslav Klát, Luboš Minář, Zdeněk Novotný, Jiřina Bartůňková, Radek Špíšek, Ladislav Pecen, Hariz Iskandar Bin Hassan, David Cibula |
|
KARCINOM PRSU NA ASCO 2018
Katarína Petráková |
|
TAILORx: Many Women With Early Breast Cancer Can Avoid Chemotherapy
Tim Donald |
|
TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score
Joseph A. Sparano, Robert James Gray, William C. Wood, et. al. |
|
Persephone Demonstrates Noninferiority of Shorter Duration Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Carina Storrs |
|
PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease- -free survival (DFS) results
Helena Margaret Earl, Louise Hiller, Anne-Laure Vallier, et. al. |
|
De-escalated treatment with trastuzumab-pertuzumab-letrozole in patients with HR+/HER2+ operable breast cancer with Ki67 response after 2 weeks letrozole: Final results of the PerELISA neoadjuvant study
Valentina Guarneri, Maria Vittoria Dieci, Giancarlo Bisagni, et. al. |
|
Adjuvant denosumab in early breast cancer: First results from the international multicenter randomized phase III placebo-controlled D-CARE study
Robert E. Coleman, Dianne Finkelstein, Carlos H. Barrios, et. al. |
|
Everolimus (EVE) + exemestane (EXE) vs EVE alone or capecitabine (CAP) for estrogen receptor- -positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): BOLERO-6, an open-label phase 2 study
Guy Heinrich Maria Jerusalem, Elena Kovalenko, Denise A. Yardley, et. al. |
|
Správa z ASCO 2018 – Gynekologické malignity
Branislav Bystrický |
|
Comparison of survival between upfront primary debulking surgery versus neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomized trial: JCOG0602
Takashi Onda, Toyomi Satoh, Toshiaki Saito, et. al. |
|
A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study
Robert L. Coleman, Danielle Enserro, Nick Spirtos, et. al. |
|
Dendritic cell vaccine (DCVAC) with chemotherapy (ct) in patients (pts) with epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Interim analysis of a phase 2, open-label, randomized, multicenter trial
Lukas Rob, Peter Mallmann, Pawel Knapp, et. al. |
|
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial canceR
David S. Miller, Giovanni Scambia, Igor Bondarenko, et. al. |
|
Comparison of different adjuvant therapy after radical surgery in early stage cervical carcinoma: A 3-arm randomized control study
He Huang, Li Yang, Yue Wei Zuo, et. al. |
|
NOVINKY Z LETOŠNÍHO SETKÁNÍ AMERICAN SOCIETY OF CLINICAL ONCOLOGY
Milada Zemanová |
|
FRONTLINE PEMBROLIZUMAB AND CHEMOTHERAPY A NEW STANDARD OF CARE IN METASTATIC SQUAMOUS NSCLC
Kara Nyberg |
|
PHASE 3 STUDY OF CARBOPLATIN-PACLITAXEL/NAB-PACLITAXEL (CHEMO) WITH OR WITHOUT PEMBROLIZUMAB (PEMBRO) FOR PATIENTS (PTS) WITH METASTATIC SQUAMOUS (SQ) NON-SMALL CELL LUNG CANCER (NSCLC)
Luis G. Paz-Ares, Alexander Luft, Ali Tafreshi, Mahmut Gumus, Julien Mazieres, Barbara Hermes, Filiz Cay Senler, Andrea Fülöp, Jeronimo Rodriguez-Cid, Shunichi Sugawara, Ying Cheng, Silvia Novello, Balazs Halmos, Yue Shentu, Dariusz Kowalski |
|
PHASE 2 STUDY OF PEMBROLIZUMAB IN ADVANCED SMALL-CELL LUNG CANCER (SCLC): KEYNOTE-158
Hyun Cheol Chung, Jose A. Lopez-Martin, Stephen Chuan-Hao Kao, Wilson H. Miller, Willeke Ros, Bo Gao, Aurelien Marabelle, Maya Gottfried, Alona Zer, Jean-Pierre Delord, Nicolas Penel, Shadia Ibrahim Jalal, Lei Xu, Susan Zeigenfuss, Scott K. Pruitt, Sarina Anne Piha-Paul |
|
NEOADJUVANT CHEMO/IMMUNOTHERAPY FOR THE TREATMENT OF STAGES IIIA RESECTABLE NON-SMALL CELL LUNG CANCER (NSCLC): A PHASE II MULTICENTER EXPLORATORY STUDY–NADIM STUDY-SLCG
Mariano Provencio-Pulla, Ernest Nadal-Alforja, Manuel Cobo, Amelia Insa, Marinha Costa Rivas, Margarita Majem, Delvys Rodriguez-Abreu, Guillermo Lopez-Vivanco, Manuel Domine, Elvira Del Barco Morillo, Bartomeu Massuti, Rosario Garcia Campelo, Alexandre Martinez Marti, Reyes Bernabé, Fernando Franco, Maria Jove, Ricardo Arrabal, Paloma Martin, Joaquin Casal, Virginia Calvo |
|
PHASE III STUDY COMPARING BEVACIZUMAB PLUS ERLOTINIB TO ERLOTINIB IN PATIENTS WITH UNTREATED NSCLC HARBORING ACTIVATING EGFR MUTATIONS: NEJ026
Naoki Furuya, Tatsuro Fukuhara, Haruhiro Saito, Kana Watanabe, Shunichi Sugawara, Shunichiro Iwasawa, Yoshio Tsunezuka, Ou Yamaguchi, Morihito Okada, Kouzou Yoshimori, Ichiro Nakachi, Akihiko Gemma, Koichi Azuma, Koichi Hagiwara, Toshihiro Nukiwa, Satoshi Morita, Kunihiko Kobayashi, Makoto Maemondo |
|
Nivolumab a chemoterapie (platinový dublet) vs. chemoterapie jako terapie 1. linie u pokročilého nemalobuněčného karcinomu plic s expresí PD-L1 < 1 % v nádoru: výsledky studie CheckMate 227
Hossein Borghaei, Matthew David Hellmann, Luis G. Paz-Ares, Suresh S. Ramalingam, Martin Reck, Kenneth John O’Byrne, Prabhu Bhagavatheeswaran, Faith Ellen Nathan, Julie R. Brahmer |
|
Léčba metastazujícího melanomu na ASCO 2018
Ivana Krajsová |
|
Neoadjuvant Nivolumab Leads to Tumor Regression in Resectable Merkel Cell Carcinoma
Muriel Cunningham |
|
Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358
Suzanne Louise Topalian, Shailender Bhatia, Ragini Reiney Kudchadkar |
|
Four-Year Data Show Durable Effect of Pembrolizumab in Advanced Melanoma
Muriel Cunningham |
|
4-YEAR SURVIVAL AND OUTCOMES AFTER CESSATION OF PEMBROLIZUMAB (PEMBRO) AFTER 2-YEARS IN PATIENTS (PTS) WITH IPILIMUMAB (IPI)-NAIVE ADVANCED MELANOMA IN KEYNOTE-006
Georgina V. Long, Jacob Schachter, Antoni Ribas, et. al. |
|
Characterization of complete responders to combination nivolumab (nivo) and ipilimumab (ipi) in patients (pts) with advanced, unresectable melanoma
Allison Betof Warner, Alexander Noor Shoushtari, Sean Houghton, et. al. |
|
Anti-PD1 antibodies in late elderly advanced melanoma patients: A retrospective multicentre study
Francesco De Rosa, Laura Ridolfi, Enrica Teresa Tanda, et. al. |
|
Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma
Reinhard Dummer, Paolo Antonio Ascierto, Helen Gogas, et. al. |
|
